SVB Securities analyst Mani Foroohar upgraded Arrowhead to Outperform from Market Perform with a price target of $35, up from $21. Shares have underperformed year-to-date relative to larger cap oligonucleotide therapy peers, yielding an appetizing risk/reward profile for shares heading into upcoming data catalysts for the pulmonary portfolio, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARWR:
- SVB Securities Likes Arrowhead Pharmaceuticals; Investors Join In
- Arrowhead upgraded to Outperform from Market Perform at SVB Securities
- Arrowhead announces first patient dosed in Takeda REDWOOD study
- Arrowhead earns $30M milestone payment from GSK through GSK4532990 trial
- Arrowhead initiated with a Market Perform at Bernstein
